Drug shortage
Methotrexate Sodium Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Methotrexate Sodium Injection |
|---|---|
| Proprietary name | Methotrexate Sodium |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Methotrexate Sodium, Injection, 50 mg/2 mL (25 mg/mL) (NDC 61703-350-38) |
| Dosage form | Injection |
| Strength | 50 mg/2 mL (25 mg/mL) |
| Status | Current |
| Therapeutic category | Oncology Rheumatology |
| Package NDCs | 61703-350-38 |
| First posted | Mar 13, 2023 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: